share_log

Cantor Fitzgerald Maintains Overweight on ProQR Therapeutics, Lowers Price Target to $4.5

Benzinga ·  May 17, 2023 09:51

Cantor Fitzgerald analyst Jennifer Kim maintains ProQR Therapeutics (NASDAQ:PRQR) with a Overweight and lowers the price target from $5 to $4.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment